Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
AEMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $8.44
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.87M
Market Cap
$2.05M
Enterprise Value-$586.88K
Total Cash (Recent Filing)$3.77B
Total Debt (Recent Filing)$573.85M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 18, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding2,598,711
10 Day Avg. Volume1,482,808
30 Day Avg. Volume5,867,838
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.29
Enterprise Value/Revenue-3.41
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$1.50Price Target Upside89.87% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first cohort of three patients in the Australian Hemopurifier cancer trial were treated without device-related serious adverse events, and the Data Safety Monitoring Board recommended advancing to the second treatment cohort.
Product DevelopmentThe amendment to include combination therapy with a PD-1 inhibitor in the Australian study was made to accelerate enrollment.
Product PotentialThe Hemopurifier is designed to improve the efficacy of anti-PD-1 therapy by depleting cancer-promoting exosomes, potentially increasing its success rate.
Bears Say
Commercialization ChallengesCapital constraints and clinical uncertainty continue to weigh on visibility, maintaining a Hold rating due to the uncertain commercialization timeline of the Hemopurifier.
Financial PerformanceAEMD did not recognize any revenue during the quarter, and revenue recognition is not forecasted for FY26 or FY27.
Market UncertaintyThere are no major catalysts expected in the next 12 months, and the company is currently facing a financial overhang.
Aethlon Medical News
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $0.60 and its highest was $8.44 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is $2.05M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2025 which is in 66 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.861 by $0.011.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Undervalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -0.51.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 2,598,711 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.861. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
Aethlon Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.50 (89.87% Upside)
$1.50 (89.87% Upside)
Blogger Sentiment
Bullish
AEMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.8%
Last 30 Days ▲ 20.9%
Last 30 Days ▲ 20.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.80%
12-Months-Change
Fundamentals
Return on Equity
-207.29%
Trailing 12-Months
Asset Growth
-53.52%
Trailing 12-Months
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
AEMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call had a positive tone overall, with significant progress reported in the Australian oncology trial and promising preclinical data in long COVID. Financial management showed effective cost reduction and strategic refocusing, although some setbacks were noted with the discontinuation of the Indian trial and a patient death in the trial.View all AEMD earnings summariesAEMD Stock 12 Month Forecast
Average Price Target
$1.50
▲(89.87% Upside)
Technical Analysis
Xylo Technologies Ltd
―
Catheter Precision
―
Bluejay Diagnostics
―
Tivic Health Systems
―
Autonomix Medical, Inc.
―
Ownership Overview
15.59% Insiders
0.82% Mutual Funds
14.76% Other Institutional Investors
68.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---